Patient | Disease | State at enrollment | Tumor features | Previous treatment |
CLL1 | Chronic lymphocytic leukemia (CLL) | Relapsed | Stage IV Rai. High-risk features, including unmutated IGHV gene status, complex karyotype, TP53 disruption (both deletion and mutation). | Ibrutinib failure. |
CLL2 | CLL | Relapsed | Stage IV Rai. Unfavorable prognostic markers including complex karyotype and TP53 mutation. | Several lines of treament: fludarabine-cyclophosphamde-rituximab, twice, rituximab single agent, BR (bendamustine-rituximab), ibrutinib, venetoclax. |
CLL3 | CLL | Naïve | Stage II Rai. Favorable prognostic variable, including mutated status of IGHV gene, normal FISH and karyotype, absence of TP53 mutation. | – |
CLL4 | CLL | Naïve | Stage II Rai. Favorable markers (mutated conformation of IGHV, 13q14 deletion and absence of both TP53 deletion or mutation). | – |
MCL1 | Mantle cell lymphoma (MCL) | Naïve | Stage IV. Absence of TP53 mutation | – |
MCL2 | MCL | Relapsed | Stage IVB blastoid variant, t(11;14) +. | Three alternating cycles of R-CHOP21 with R-DHAOx (total cycles n=6) and autologous stem cell transplantation.Ibrutinib failure. |
SMZL1 | Splenic marginal zone lymphoma (SMZL) | Naïve | Stage IV | – |
SMZL2 | SMZL | Relapsed | Stage IVA, extranodal localization. | Splenectomy, BR, ibrutinib and venetoclax. |
B-ALL1 | Early B cell precursor acute lymphoid leukemia (B-ALL) | Relapsed | High-risk according to 2016 WHO classification: t(t;11) (4q21;11q23). | Prephase: cyclophosphamide and prednisone. I cycle: idarubicin, dexamethasone, vincristine e peg- asparaginase. II cycle: idarubicin, cyclophosphamide, cytarabine, 6-mercaptopurine, dexamethasone. Intrathecal therapy with methotrexate, cytarabine and dexamethasone. III cycle: methotrexate and cytarabine. At first relapse received dexamethasone for 2 days and vincristine for 1 day as debulking, followed by blinatumomab according to conventional doses and schedule. Blood sample was taken at the second relapse. |
IGHV, immunoglobulin heavy chain variable.